Metropolitan Life Insurance CO Coherus Bio Sciences, Inc. Transaction History

Metropolitan Life Insurance CO

$2.27 Billion
Q1 2024

A detailed history of Metropolitan Life Insurance CO transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Metropolitan Life Insurance CO holds 2,365 shares of CHRS stock, worth $4,091. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,365

Previous 2,779 14.9%

Holding current value

$4,091

Previous $9,000 44.44%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$2.02 - $3.14 $836 - $1,299	-414 Reduced 14.9%	2,365 $5,000
Q4 2023 Feb 14, 2024	SELL	$1.59 - $3.85 $4,905 - $11,877	-3,085 Reduced 52.61%	2,779 $9,000
Q3 2023 Nov 14, 2023	BUY	$3.74 - $5.45 $6,773 - $9,869	1,811 Added 44.68%	5,864 $21,000
Q2 2023 Aug 10, 2023	BUY	$3.79 - $8.3 $15,360 - $33,639	4,053 New	4,053 $17,000
Q4 2022 Jun 14, 2023	BUY	$5.69 - $10.07 $24,176 - $42,787	4,249 New	4,249 $33.7 Million

Q3 2022 Jun 14, 2023	BUY	$7.17 - $13.87 $30,465 - $58,933	4,249 New	4,249 $40.8 Million
Q2 2022 Jun 20, 2023	BUY	$5.86 - $13.23 $24,899 - $56,214	4,249 New	4,249 $30,000
Q1 2022 Jun 20, 2023	BUY	$10.92 - $16.41 $46,399 - $69,726	4,249 New	4,249 $54,000
Q1 2022 Mar 30, 2023	SELL	$10.92 - $16.41 $148,118 - $222,585	-13,564 Reduced 76.15%	4,249 $54,000
Q1 2022 May 12, 2022	SELL	$10.92 - $16.41 $148,118 - $222,585	-13,564 Reduced 76.15%	4,249 $55,000
Q4 2021 Jun 21, 2023	BUY	$15.81 - $18.99 $281,623 - $338,268	17,813 New	17,813 $284,000
Q3 2021 Jun 21, 2023	BUY	$12.68 - $17.79 $225,868 - $316,893	17,813 New	17,813 $286,000
Q2 2021 Mar 30, 2023	BUY	$12.95 - $15.41 $24,864 - $29,587	1,920 Added 12.08%	17,813 $246,000
Q2 2021 Aug 16, 2021	BUY	$12.95 - $15.41 $230,471 - $274,251	17,797 Added 111231.25%	17,813 $246,000
Q1 2021 Jun 26, 2023	BUY	$14.42 - $21.39 $229,177 - $339,951	15,893 New	15,893 $232 Million
Q1 2021 Mar 30, 2023	BUY	$14.42 - $21.39 $167,906 - $249,065	11,644 Added 274.04%	15,893 $232,000
Q1 2021 May 14, 2021	BUY	$14.42 - $21.39 $230 - $342	16 New	16 $232,000
Q4 2020 Jun 22, 2023	BUY	$16.56 - $18.94 $294,585 - $336,923	17,789 New	17,789 $309 Million
Q3 2020 Jun 26, 2023	BUY	$17.41 - $19.89 $309,706 - $353,823	17,789 New	17,789 $326 Million
Q2 2020 Jun 26, 2023	BUY	$14.43 - $19.16 $292,842 - $388,833	20,294 New	20,294 $362 Million
Q1 2020 Jul 12, 2023	BUY	$11.67 - $22.53 $236,830 - $457,223	20,294 New	20,294 $329 Million
Q4 2019 Jul 12, 2023	BUY	$16.33 - $21.37 $325,799 - $426,352	19,951 New	19,951 $359 Million
Q3 2019 Jul 12, 2023	BUY	$16.3 - $23.37 $338,143 - $484,810	20,745 New	20,745 $420 Million
Q2 2019 Jul 12, 2023	BUY	$13.1 - $22.1 $223,630 - $377,269	17,071 New	17,071 $377 Million
Q1 2019 Jul 13, 2023	BUY	$8.38 - $15.5 $143,054 - $264,600	17,071 New	17,071 $233 Million
Q4 2018 Jul 13, 2023	BUY	$8.65 - $16.28 $147,664 - $277,915	17,071 New	17,071 $154 Million
Q3 2018 Jul 13, 2023	BUY	$14.45 - $20.25 $229,335 - $321,387	15,871 New	15,871 $262 Million

Others Institutions Holding CHRS

# of Institutions

148

Shares Held

82.9M

Call Options Held

184K

Put Options Held

255K

View Full List

About Coherus BioSciences, Inc.

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $134M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

More about CHRS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.

Account

Metropolitan Life Insurance CO Coherus Bio Sciences, Inc. Transaction History